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The presently-disclosed subject matter provides methods for 
preventing ischemia in a cell, treating ischemia in a subject, 
and preventing an infarction in a subject that utilize a5~1 
integrin inhibitor. In some instances, a5 ~ 1 integrin inhibitor 
is administered to a subject prior to, during, or after the onset 
of ischemia to treat the ischemia and/or prevent infarction. In 
some instances the present methods prevent the occurrence of 
an infarction. In some instances the present methods restores 
perfusion to organs and tissues. 
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COMPOSITIONS AND METHODS FOR 
TREATING ISCHEMIA 
RELATED APPLICATIONS 
2 
DESCRIPTION OF THE DRAWINGS 
Illustrative aspects of embodiments of the present inven-
tion will be described in detail with reference to the following 
figures wherein: 
FIG. lA includes images of brains where carbon black ink 
was injected into the cerebral vasculature showing the left 
hemisphere, where the shaded region indicates the territory of 
the middle cerebral artery (MCA). 
This application claims the benefit of U.S. Provisional 
Patent Application No. 61/938,621, filed Feb. 11,2014, the 
entire disclosure of which is hereby incorporated by refer-
ence. 
10 FIG.lB includes a plot showing the quantification ofMCA 
GOVERNMENT INTEREST territory area in control and a5 KO (knockout) mice brains 
shown in FIG. lA. N=6. Bars=SD. 
This invention was made with government support under 
Grant No. 2R~1NS065842-08 the awarded by the National 
Institutes of Health. The government has certain rights in the 
invention. 
FIG. 2A includes images oflaser speckle doppler flow of 
WT (wild type) and a5 integrin KO mice at just prior and 
15 immediately following (L)eft MCAo. 
TECHNICAL FIELD 
FIG. 2B includes a plot showing levels of perfusion for the 
samples WT and a5 integrin KO mice at just prior and imme-
diately following (L)eft MCAo, where the data are obtained 
from the respective circled areas shown in FIG. 2A (N=3 
The presently-disclosed subject matter relates to the treat-
ment of ischemia, including cerebral ischemia and stroke. In 
particular, embodiments of the presently-disclosed subject 
matter relate to methods for preventing and/or treating 
ischemia and potential infarction that utilize an a5 ~ 1 integrin 
inhibitor. 
20 animals per group, *P<0.05). 
FIG. 3A includes images showing TTC in WT and a5 
integrin KO mice brains 3 days after MCAo (PSD 3), where 
arrows indicate TTC negative areas. 
FIG. 3B includes a plot showing the quantification of mean 
25 infarct volumes of the mice brains shown in FIG. 3A (N=18 
per group per PSD, 3 separate experiments, *P<O.OOl). 
INTRODUCTION 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction with possible irreversible organ dam-
age. Cerebral ischemia results from decreased blood and oxy-
gen flow implicating one or more of the blood vessels of the 
brain. In cerebral ischemia, the individual suffers a stroke 
with sudden development of a focal neurologic deficit and, in 
most cases, some degree of brain damage. The decreased 
blood flow may be due to, for example, an occlusion such as 
FIG. 4 includes images of a cresyl violet stain of stroke-
affected and contralateral brain areas showing a significant 
neuronal cell dropout and pyknotic appearing neurons in WT 
30 mice but no appreciable cell dropout and relatively few 
pyknotic appearing neurons in a5 integrin KO mice. Scale 
bar=50 fllll· 
FIG. 5 includes images of TUNEL stains with DAPI 
nuclear counterstains of stroke-affected brain areas showing 
35 substantial and increased apoptosis in WT mice from PSD 1-3 
but minimal apoptosis in a5 integrin KO mice (n=3). Scale 
bar is 50 f.tm. 
a thrombus or embolus, vessel rupture, sudden fall in blood 
pressure, change in the vessel lumen diameter due to athero-
sclerosis, trauma, aneurysm, developmental malformation, 
altered permeability of the vessel wall or increased viscosity 
FIG. 6 includes images showing IgG (DAB stain) immu-
nohistochemistry of stroked brain tissue on PSD 1 and 3 that 
40 were counterstained with hematoxylin. N=6. Scale bar is 50 
f.tm. 
or other quality of the blood. Decreased blood flow may also 
be due to failure of the systemic circulation and severe pro-
longedhypotension. Ischemic necrosis of the spinal cord may 45 
result in sensory or motor symptoms or both that can be 
referred to cervical, thoracic or lumbar levels of the spine. 
Current treatments for ischemia encompass behavioral 
changes, drug therapy, and/or surgical intervention. Drugs are 
frequently preferred before resorting to invasive procedures 50 
and to provide more immediate relief than long-term behav-
ioral changes. However, current drugs are limited in their 
effectiveness in preventing infarction. 
Similarly, stroke is the fourth leading cause of death in the 
U.S., and approximately 87% of stroke patients are ischemic, 55 
resulting from a lack of blood flow to a part of the brain. 
Current standard of care for ischemic stroke is rapid reopen-
ing of the occluded brain blood vessel with tissue plasmino-
gen activator (t-PA). Unfortunately, t-PA is limited to a brief 
window of 4.5 hours within symptom onset contributing, 60 
along with other factors, to the exclusion of many patients. 
Furthermore, results from large t-PA trials have been mixed, 
showing improving recanalization rates, but no overwhelm-
ing improvements in outcome. 
Thus, there is a need for a therapeutic agent which can be 65 
useful in treating ischemia as well as associated infarction and 
cell death. 
FIG. 7A includes images ofPSD3 TTC stained brain sec-
tions showing WT mice treated with intravenous PBS (Con-
trol) or ATN -161 (1 mg/kg) on PSD 1. 
FIG. 7B includes a plot showing the quantification of mean 
infarct volume of the mice samples shown in FIG. 7A (ex-
pressed as a percent of control normalized to 100%). N=12, 
*P<0.05. 
FIG. 7C includes images of TUNEL stain with DAPI 
nuclear counterstain showing stroke-affected brain areas on 
PSD3 as labeled, and demonstrating increased apoptosis in 
PBS treated versus ATN -161 treated mice. Scale bar is 50 f.tm. 
FIG. SA includes a schematic showing that activation of 
a5~1 integrin by fibronectin increases inhibition of PKA, 
lowers levels of phosphorylation-mediated activation ofGDI, 
increases levels of dissociated and active RhoA, increases 
activation of ROCK!, causes actin stress fiber rearrangement 
and phosphorylation of claudin-5 at position T207, creates a 
less tight junction integrity and increases BBB permeability, 
and subsequently leads to endothelial cell activation and 
increases a5~1 integrin expression. 
FIG. SB includes a schematic showing that inhibition or 
absence of the a5~1 integrin prevents inhibition of PKA, 
increases phosphorylation-mediated activation of GDI, and 
creates no dissociation of RhoA as well as reduces ROCK! 
activation, rearranges F -actin, and phosphorylizes claudin-5. 
This increases tight junction connections between endothe-
US 9,370,547 B2 
3 
lial cells decreases permeability and cellular activation, and 
prevents increase in aS~ 1 expression and endothelial cell 
activation. 
FIG. 9 includes a plot of post-OGD FITC-dextran perme-
ability measurements across the monolayer of confluent (6 
days) WT mouse brain endothelial cells exposed to OGD for 
8 hours+/-ATN-161 (10 f.LM added 4 hours after OGD) and 
then returned to normoxic and normoglycemic conditions. 
Results shown as a percentage of pre-OGD FITC-dextran 
fluorescence in untreated WT cells, normalized to 100% 
(dashed line). **p<O.Ol. N=4. 
FIG. lOA includes a Western blot for aS integrin from WT 
mouse brain endothelial cells+/-ATN-161 before and after 
OGD as labeled. 
FIG. lOB includes a plot showing the quantification (mean 
values) of aS western blots (as in FIG. lOA) normalized to 
Ponceau S. total protein stain and expressed as a % change 
from PBS treated pre-OGD cells. N=3. *p<O.OS. 
FIG. llA includes a claudin-S western blot ofbrain endot-
helial cells after OGD that were treated as labeled. 
FIG. llB includes plot showing the quantification of clau-
din-S expression normalized to Ponceau S total protein stain 
for the samples show in FIG. llA. 
FIG. llC includes images showing claudin-S immunocy-
tochemistry of WT mouse brain endothelial cells either just 
prior to (control) or 24 hours after OGD treated as labeled. 
Scale bar is S f.Lm. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. Modi-
fications to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the specific details of the described exemplary 
embodiments, is provided primarily for clearness of under-
standing, and no unnecessary limitations are to be understood 
therefrom. 
The presently disclosed subject matter is directed to pre-
venting and/or treating ischemia with methods that involve 
use of an aS~1 integrin inhibitor. As is known in the art, 
ischemia can lead to infarction in a subject. Therefore, the 
presently-disclosed subject matter further relates to methods 
for preventing and/or treating an infarction in a subject, and 
such methods involve the use of an aS~ 1 integrin inhibitor. 
4 
degree of reduction or elimination of ischemia. Likewise, the 
term "preventing" does not imply that infarction due to 
ischemia is eliminated. Instead, the term "preventing" refers 
to reducing ischemia as well as side effects thereof, including 
potentially infarction, by about 1, 2, 3, 4, S, 6, 7, 8, 9, 10, 11, 
12, 13,14, 1S, 16, 17, 18,19,20,21,22,23,24,2S,26,27,28, 
29,30,31,32,33,34,3S,36,37,38,39,40,41,42,43,44,4S, 
46,47,48,49,SO,S1,S2,S3,S4,SS,S6,S7,S8,S9,60,61,62, 
63,64,6S,66,67,68,69,70, 71, 72, 73, 74,7S, 76, 77, 78, 79, 
10 80,81,82,83,84,8S,86,87,88,89,90,91,92,93,94,9S,96, 
97, 98, 99, or 100% relative to a control that has not been 
contacted or treated with an aS~ 1 integrin inhibitor. 
Furthermore, the terms "inhibitor" and the like do not 
necessarily refer to the ability to completely inactivate all 
15 target biological activity in all cases. Rather, the skilled arti-
san will understand that the term "inhibitor" refers to a sub-
stance that can decrease biological activity of a target, such as 
can occur with a ligand binding site of the target, or protein in 
a biochemical pathway of the target is blocked, or when a 
20 non-native complex with the target, or protein in a biochemi-
cal pathway of the target, is formed. Such decrease in bio-
logical activity can be determined relative to a control, 
wherein an inhibitor is not administered and/or placed in 
contact with the target. Accordingly, the term "aS~ 1 integrin 
25 inhibitor" refers to substances that can decrease or eliminate 
aS~ 1 integrin activity, optionally relative to a control that has 
not been contacted with an aS~1 integrin inhibitor. In some 
embodiments, a decrease in aS~1 integrin activity relative to 
a control can be about a 1, 2, 3, 4, S, 6, 7, 8, 9, 10, 11, 12, 13, 
30 14, 1S,16, 17, 18, 19,20,21,22,23,24,2S,26,27,28,29,30, 
31,32,33,34,3S,36,37,38,39,40,41,42,43,44,4S,46,47, 
48,49,SO,S1,S2,S3,S4,SS,S6,S7,S8,S9,60,61,62,63,64, 
6S,66,67,68,69, 70, 71,72, 73, 74, 7S, 76,77, 78, 79,80,81, 
82,83,84,8S,86,87,88,89,90,91,92,93,94,9S,96,97,98, 
35 99, or 100% decrease. 
In some embodiments, the aS~1 integrin inhibitor is 
selected from small molecule and a polypeptide. 
As used herein, the term "polypeptide" means any polymer 
comprising any of the 20 protein amino acids, regardless of its 
40 size. Although "protein" is often used in reference to rela-
tively large polypeptides, and "peptide" is often used in ref-
erence to small polypeptides, usage of these terms in the art 
overlaps and varies. The term "polypeptide" as used herein 
refers to peptides, polypeptides and proteins, nnless other-
45 wise noted. As used herein, the terms "protein," "polypep-
tide," and "peptide" are used interchangeably herein when 
referring to a gene product. Unless otherwise indicated, a 
particular polypeptide also implicitly encompasses conserva-
tively-substituted variants thereof. 
As used herein, "small molecule" refers to a non-peptidic, 
non-oligomeric organic compound either synthesized in the 
laboratory or fonnd in nature. Small molecules, as used 
herein, can refer to compounds that are "natural product-
like," however, the term "small molecule" is not limited to 
In some embodiments, a method is provided for preventing 
ischemia in a cell, wherein the ischemia may be caused by one 50 
or more ischemic events. In some embodiment the method 
includes contacting the cell with an aS~1 integrin inhibitor. 
The term "contacting" as used herein refers to any means by 
which an aS~ 1 integrin inhibitor brought into sufficient prox-
imity and/or in direct contact with a cell such that the cell is 
capable of receiving the aS~ 1 integrin inhibitor. For instance, 
55 "natural product-like" compounds. Rather, a small molecule 
is typically characterized in that it possesses one or more of 
the following characteristics including having several car-
bon-carbon bonds, having multiple stereocenters, having 
multiple functional groups, having at least two different types 
in some embodiments contact refers to coating a cell with an 
aS~ 1 integrin inhibitor. In other embodiments contact refers 
to culturing a cell in a solution that includes an aS~ 1 integrin 
inhibitor. In other embodiments the cell is within a subject, 
and contact refers to administering an aS~ 1 integrin inhibitor 
to the subject such that a cell within the subject is capable of 
receiving an aS~1 integrin inhibitor. 
The term "preventing" as used herein refers to the charac-
teristic of reducing or eliminating ischemia as well as the side 
effects associated with ischemia, which can include infarc-
tion. The term "preventing" does not imply a particular 
60 of functional groups, and having a molecular weight of less 
than 1SOO, although this characterization is not intended to be 
limiting for the purposes of the disclosure. 
In some embodiments the aS~1 integrin inhibitor is 
selected from ATN-161, Ac-PhScN-NH2 , CRRETAWAC 
65 (SEQ. ID NO: 1) aS~1 integrin inhibitor peptide, and com-
binations thereof. ATN-161 is a peptide with the amino acid 
sequence PHSCN that has been developed to inhibit aS~ 1 
US 9,370,547 B2 
5 
integrin and has successfully completed Phase I and Phase II 
clinical trials for recurrent intracranial malignant glioma. 
Among other things, ATN-161 can be safely administered 
intravenously, has a relatively short serum half-life (e.g., 3-5 
h for some subjects) with high tissue distribution, and local-
izes to vasculature over-expressing activated, but not unacti-
vated, a5~1 integrin. ATN-161, in addition to noncovalent 
interaction with the a5 integrin subunit, can have a covalent 
interaction with the ~1 and ~3 subunit of a5~1 and av~3 
integrin. 
Ac-PhScN-NH2 is a modified version of ATN-161 in 
which the covalent interaction is eliminated by replacing the 
Hand C with D-stereoisomers. Ac-PhScN-NH2 specifically 
and noncovalently interacts with the a5 subunit of a5~1 
integrin and is between 27,000 fold and 379,000 fold more 
potent and specifically inhibits activated a5 ~ 1 integrin medi-
ated processes. 
In some embodiments the a5~ 1 integrin inhibitor includes 
6 
tion, subcutaneous administration, intravitreous administra-
tion, intracameral (into anterior chamber) administration, and 
the like. Administration can be continuous or intermittent. In 
various aspects, a preparation can be administered therapeu-
tically; that is, administered to treat an existing disease or 
condition (e.g., ischemia, infarction, etc.). In other instances 
a preparation is administered prophylactically; that is, admin-
istered to prevent or treat a disease or condition that may 
otherwise develop. 
10 As used herein, the terms "effective amount" and "thera-
peutically effective amount" are used interchangeably and 
mean a dosage sufficient to provide treatment. The exact 
amount that is required will vary from subject to subject, 
15 depending on the species, age, and general condition of the 
subject, the particular carrier or adjuvant being used, mode of 
administration, and the like. As such, the effective amount 
will vary based on the particular circumstances, and an appro-
priate effective amount can be determined in a particular case a CRRETAWAC a5~1 integrin inhibitor peptide. See, e.g., 
Koivunen E, Wang B, Ruoslahti E. Isolation of a highly 
specific ligand for the alpha 5 beta 1 integrin from a phage 
display library. J Cell Biol. 1994; 124(3):373-380. In some 
embodiments the a5~1 integrin inhibitor is selected from an 
a5~1 integrin antibody that inhibits the function of the a5~1 
integrin inhibitor. Those of ordinary skill in the art will rec- 25 
ognize antibodies for blocking the function of aS~ 1 integrin, 
20 by one of ordinary skill in the art using only routine experi-
mentation. 
In some instances an effective amount is determined rela-
tive to the weight of a subject, and can be selected from 
dosages of about 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 
mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 
mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 
as well as such antibodies suited for use in particular subjects, 
including human and non-human subjects. 
Additionally, without being bound by theory or mecha-
nism, relatively small peptides such as ATN-161, Ac-Ph- 30 
ScN-NH2 and CRRETAWAC (SEQ ID NO: 1) a5~1 inte-
grin inhibitor peptide may not be able to cross the intact 
blood-brain barrier (BBB), like other small peptides cannot. 
This characteristic can be advantageous for targeting circula-
tion accessible activated brain endothelial cell a5~1 integrin 35 
to potentially stabilize the BBB. 
17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 21 mg/kg, 22 
mg/kg, 23 mg/kg, 24 mg/kg, 25 mg/kg, 26 mg/kg, 27 mg/kg, 
28 mg/kg, 29 mg/kg, 30 mg/kg, 31 mg/kg, 32 mg/kg, 33 
mg/kg, 34 mg/kg, 35 mg/kg, 36 mg/kg, 37 mg/kg, 38 mg/kg, 
39 mg/kg, 40 mg/kg, 41 mg/kg, 42 mg/kg, 43 mg/kg, 44 
mg/kg, 45 mg/kg, 46 mg/kg, 47 mg/kg, 48 mg/kg, 49 mg/kg, 
and 50 mg/kg. 
The term "subject" is used herein to refer to a target of 
administration, which optionally displays symptoms related 
to a particular disease, pathological condition, disorder, or the 
like. Thus, in some embodiments a subject refers to a target 
that displays symptoms of ischemia and/or infarction. The 
subject of the herein disclosed methods can include both 
With respect to methods for preventing ischemia in a cell, 
in some embodiments the cell is a brain cell. In other embodi-
ments the cell is part of a particular tissue, and the method 
includes preventing ischemia in the cell(s) of the tissue. In this 
respect, the term "tissue" is used herein to refer to a popula-
tion of cells, generally consisting of cells of the same kind that 
perform the same or similar functions. The types of cells that 
make the tissue are not limited. In some embodiments tissue 
is part of a living organism, and in some embodiments tissue 
is tissue excised from a living organism or artificial tissue. In 
some embodiments tissue can be part of an organ, wherein the 
term "organ" refers to a part of a subject which is composed 
of several tissues and adapted to perform a specific function 
or functions, such as the brain. 
The presently-disclosed subject matter also relates to 
methods for treating ischemia in a subject. In some embodi-
ments the method comprises administering to the subject an 
effective amount of an a5~1 integrin inhibitor. In some 
embodiments the a5~1 integrin inhibitor is selected from 
small molecule and a polypeptide. In some embodiments the 
a5~1 integrin inhibitor is selected from ATN-161, Ac-Ph-
ScN-NH2 CRRETAWAC (SEQ ID NO: 1) a5~1 integrin 
inhibitor peptide, and combinations thereof. 
The term "administering" refers to any method of provid-
ing an a5~1 integrin inhibitor and/or pharmaceutical compo-
sition thereof to a subject. Such methods are well known to 
those skilled in the art and include, but are not limited to, oral 
administration, transdermal administration, nasal administra-
tion, intracerebral administration, and administration by 
injuction, which itself can include intravenous administra-
tion, intra-arterial administration, intramuscular administra-
40 human and animal subjects. A subject can be, but is not 
limited to, vertebrates, such as mammals, fish, birds, reptiles, 
or amphibians. More specifically, the subject of the herein 
disclosed methods can include, but is not limited to, a human, 
non-human primate, cat, dog, deer, bison, horse, pig, rabbit, 
45 dog, sheep, goat, cow, cat, guinea pig, or rodent. The term 
does not denote a particular age or sex. Adult and newborn 
subjects, as well as fetuses, whether male or female, are 
intended to be covered. The term "subject" includes human 
50 
and veterinary subjects. 
The terms "treat," "treatment," and the like refer to the 
medical management of a subject with the intent to cure, 
ameliorate, stabilize, or prevent a disease, pathological con-
dition, or disorder. This term includes active treatment, that is, 
treatment directed specifically toward the improvement of a 
55 disease, pathological condition, or disorder, and also includes 
causal treatment, that is, treatment directed toward removal of 
the cause of the associated disease, pathological condition, or 
disorder. In addition, this term includes palliative treatment, 
that is, treatment designed for the relief of symptoms rather 
60 than the curing of the disease, pathological condition, or 
disorder; preventative (prophylatic) treatment, that is, treat-
ment directed to minimizing or partially or completely inhib-
iting the development of the associated disease, pathological 
condition, or disorder; and supportive treatment, that is, treat-
65 ment employed to supplement another specific therapy 
directed toward the improvement of the associated disease, 
pathological condition, or disorder. 
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Those of ordinary skill in the art will recognize factors and 
methods for diagnosing and/or prognosing a subject with 
ischemia. Factors that can contribute to a diagnosis and/or 
prognosis of ischemia in a subject include, but are not limited 
to, hypercholesterolemia, electrocardiogram (EKG) changes 
associated with a risk of or the presence of ischemia (e.g., 
peaked or inverted T-waves or ST segment elevations or 
depression in an appropriate clinical context), sedentary lif-
estyles, angiographic evidence of partial coronary artery 
In some methods for treating ischemia, the ischemia is 
caused by a particular ischemic event. In some instances, the 
ischemia is caused at least in part by an ischemic event 
selected from cerebral ischemia, stroke, and a combination 
thereof. In some embodiments the aS~1 integrin inhibitor is 
administered one or more times during or after the onset of 
ischemia and/or during or after an ischemic event. In this 
respect, in some embodiments an aS~1 integrin inhibitor is 
administered one or more times during or after the onset of 
two or more distinct ischemic events, and therefore the 
present methods are not limited to a single administration of 
an aS~1 integrin inhibitor. In such embodiments, the aS~1 
integrin inhibitor can optionally be administered about O.S, 1, 
10 obstruction, evidence of a cerebrovascular accident CVA, and 
other clinical evidence of ischemia 
2, 3, 4, s, 6, 7, 8, 9, 10, 11, 12, 13, 14, 1S, 16, 17, 18, 19, 20, 
21, 22, 23, 24, 2S, 26, 27, 28, 29, or 30 hours after the onset of 15 
the ischemic. 
EXAMPLES 
The presently-disclosed subject matter is further illustrated 
by the following specific but non-limiting examples. The 
examples may include compilations of data that are represen-
tative of data gathered at various times during the course of 
development and experimentation related to the presently-
As discussed above, treatment can be preventative (pro-
phylactic) in some instances. Accordingly, in some embodi-
ments of the presently-disclosed treatment methods, the 
aS~1 integrin inhibitor is administered prior to the onset of 
ischemia and/or prior to an ischemic event. In some embodi-
ments the aS~1 integrin inhibitor is administered prior to 
each of one or more separate onsets of ischemia and/or 
ischemic events. 
20 disclosed subject matter. Furthermore, some of the examples 
described herein may be prophetic examples. 
In some embodiments administration of an aS~ 1 integrin 25 
inhibitor to a subject, prior to, during, and/or after the onset of 
ischemia, can prevent (i.e., 1-100% reduction relative to con-
trol) the occurrence of infarction in the subject. Alternatively 
or additionally, in some embodiments administration of an 
aS~1 integrin inhibitor to a subject, prior to, during, and/or 30 
after the onset of ischemia, can restore perfusion to tissues 
and organs in the subject. 
Further still, the presently-disclosed subject matter relates 
to methods for preventing an infarction in a subject. In some 
embodiments, a method for preventing an infarction in a 35 
subject comprises administering an effective amount of an 
aS~ 1 integrin inhibitor. In some embodiments the aS~ 1 inte-
grin inhibitor is selected from small molecule and a polypep-
tide. In some embodiments the aS~1 integrin inhibitor is 
selected from ATN-161, Ac-PhScN-NH2 CRRETAWAC 40 
(SEQ ID NO: 1) aS~ 1 integrin inhibitor peptide, and combi-
nations thereof. 
Example 1 
This Example demonstrates that stroke-induced upregula-
tion and activation of an aS~1 integrin allows systemically 
administered domain V (DV) protein fragment of the brain 
extracellular matrix proteoglycan perlecan to target a stroke 
site. This Example therefore links the therapeutic effect of 
DV to aS~ 1 integrin. 
A transient middle cerebral artery occlusion (MCAo) was 
performed in 3 month old male mice that had endothelial cell 
selective knockdown of the aS integrin (referred to hereafter 
as "aS integrin KO mice"). As the aS integrin subunit is 
known to only heterodimerize with the ~ 1 integrin subunit, 
this mouse is effectively deficient in endothelial cell aS~1 
integrin. These mice were healthy, fertile, and had no spon-
taneous vascular or hematopoietic phenotypes, no alterations 
in developmental vasculogenesis or angiogenesis, no differ-
ences in vascular extracellular matrix composition or struc-
ture, and no disparities in their subsets ofhematopoietic cells. 
Furthermore, these mice localized more av~3 at the brain 
endothelial cell surface in their focal adhesions, but exhibited 
no increase in total av~S protein. Brain angiogenesis in the 
In some embodiments of methods for preventing an infrac-
tion in a subject, prior to administering an aS~1 integrin 
inhibitor, the subject is first diagnosed and/or prognosed as 
having ischemia. In some instances the subject can be diag-
nosed as having ischemia that has already led to an infarction 
45 face of chronic (14 days) hypoxia was significantly delayed in 
these mice. 
Relative to wild type (WT) littermates, analysis of the aS 
integrin KO mice demonstrated no significant differences in 
their cerebrovascular anatomy that could otherwise explain 
in the subject. Administration of an aS~1 integrin inhibitor 
prior to an ischemic event, whether or not a subject has been 
prognosed as being at risk for ischemia, could therefore serve 
as a preventative treatment for ischemia, and potentially inf-
arction. 
50 any differences in experimental infarct size (FIGS. lA and 
lB), no significant difference in brain microvascular density 
as quantified by immunohistochemistry, and no significant 
differences in blood gas parameters. During the stroke sur-
gery, both aS integrin KO and WT littermates experienced 
The terms "diagnose" and the like as used herein refer to 
methods by which the skilled artisan can estimate and even 
determine whether or not a subject is suffering from a given 
disease or condition, such as ischemia. Along with diagnosis, 
clinical "prognosis" or "prognosticating" is also an area of 
great concern and interest, and the terms "prognose" and the 
like refer to act of determining the relative risk associated 
with particular conditions in order to plan the most effective 60 
therapy. If an accurate prognosis can be made, appropriate 
therapy, and in some instances less severe therapy or more 
effective therapy, for the subject can be chosen. For instance, 
55 similar degradations in blood flow upon MCAo as measured 
by laser speckle Doppler (Peri Cam PSI HR, Perimed, FIGS. 
2A and 2B), reducing the likelihood that potential differences 
in collateral circulation could account for differences in inf-
arct size. 
in some embodiments of the presently disclosed subject mat-
ter, a subject that is prognosed as having ischemia can have an 65 
aS~1 integrin inhibitor administered in order to prevent the 
potential ischemia from developing. 
It was noted that the KO mice had little to no discernible 
infarction, as measured by (TTC) and little sign of neuronal 
injury (i.e., small, rounded, pyknotic appearing neurons by 
cresyl violet stain) or apoptotic cell death from PSD1-3 
(FIGS. 3 to 5). This degree of apparent resistance to ischemic 
stroke injury is superior to other known genetically modified 
mice. The lack of neuronal injury/death was associated with a 
qPCR-measured decrease in the transcription of several pro-
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MCAo and assessed mean infarct volume and the extent of 
TUNELpositive apoptosis onPSD3 (FIGS. 7A to 7C, N=12, 
two separate experiments). ATN-161 treatment resulted in 
little to no TTC detected infarct and minimal apoptosis, sup-
inflammatory cytokines (e.g. IL-l beta and TNFalpha were 
0.33 fold and 0.34 fold, respectively, of PSD3 WT stroked 
control levels, p<O.Ol, n=3) and an increase in several anti-
inflammatory cytokines (e.g., IL-4 and IL-10 were 131.87 
fold and 2S.34 more than PSDl WT stroked control levels, 
p<O.OOl, n=3) in ipsilateral ischemic brain. These observa-
tions collectively suggest that after MCAo, aS integrin KO 
mice experience a combination ofless inflammation and little 
to no neuronal death in ischemic areas. 
5 porting the notion that pharmacologically targeting the aS~ 1 
integrin in stroked subjects can be therapeutic. Additionally, 
treatment withATN-161 did not alter animal vital signs upon 
administration and was well tolerated, as indicated by a lack 
of signs of illness such as fur ruffling, weight differences, and 
10 the like. In this regard, one of the more prominent ways in which 
ischemic brain injury expands is via disruption of the blood-
brain barrier (BBB), allowing for cytotoxic and vasogenic 
edema, infiltration of immune and inflammatory cells, and the 
like. For this reason, limiting poststroke BBB disruption was 
examined for potential therapeutic benefits. The BBB appears 15 
to open and close repeatedly after transient ischemic stroke. 
Typically, the hyperemia associated with reperfusion is asso-
ciated with increased BBB opening, followed by a refractory 
period of slight hypoperfusion and a closed BBB, which is 
then followed by a biphasic period of BBB opening. Without 20 
being bound by theory or mechanism, the earlier periods of 
BBB opening may be due to increased endothelial transcyto-
sis, while the final opening period, which typically occurs 
between 18-96 hours after reperfusion, is associated with 
increased paracellular permeability due to disruption of tight 25 
junction (TJ) proteins such as claudin-S, vasogenic edema, 
inflammatory cell infiltration, and the initiation of angiogen-
esis. 
As discussed above, aS~l integrin is a mediator in the 
angiogenic response, and is upregulated in stroke-affected 30 
vasculature during the first 24 hours in the MCAo model. 
Additionally, the difference in neuronal injury and inflamma-
tory mediator transcription in the aS integrin KO mice was 
evident as early as 24 hours post MCAo. Thus, the deletion of 
this single endothelial cell integrin may cause such neuropro- 35 
tection by preventing the final BBB opening by stabilizing TJ 
proteins, thereby minimizing ischemic injury after transient 
MCAo. 
Example 2 
Example 4 
This Example describes procedures performed to charac-
terize the role of aS~l integrin in modulating blood-brain 
barrier integrity and subsequent resistance to ischemic stroke. 
Based on the results of the previous Examples that aS integrin 
KO mice appear to resist post-stroke BBB breakdown after 
transient MCAo, and that post-stroke claudin-S gene expres-
sion increases in these mice, it appears that suppression of 
brain endothelial cell aS~ 1 integrin in an ischemia -affected 
brain is neuroprotective, at least in part, by stabilization of the 
post-stroke BBB via increased expression and function of 
claudin-S. 
Without being bound by theory or mechanism, claudin-S 
stabilization, in addition to reducing paracellular permeabil-
ity, could result in less cell surface expression of aS~l inte-
grin, less endothelial cell activation, and less transcellular 
permeability. Based on previous results, it appears that aS~ 1 
is linked to protein kinase a (PKA), PKA to Ras homolog 
family member A (RhoA) and barrier stability effects, and 
RhoA to claudin-S function via Rho-associated coiled-coil 
containing protein kinase 1 (ROCK!) mediated phosphory-
lation. Without being bound by theory or mechanism, a sche-
matic for aS~ 1 mediation of tight junction (TJ) protein func-
tion and BBB permeability is summarized in FIGS. SA and 
SB. 
This Example describes procedures performed to further 
characterize the effect of endothelial cell selective aS~ 1 inte-
grin deletion on experimental ischemic stroke. 
To determine whether inhibition of aS~l integrin with 
ATN -161 in brain endothelial cells has any effect on their 
permeability under baseline or stroke-like conditions (oxy-
40 gen-glucose deprivation (OGD)-reperfusion) in vitro, FITC 
dextran permeability experiments were performed with a 
CS7BI6 WT brain endothelial cell line+/-ATN -161. While no 
differences were noted in FITC dextran permeability in non-
In addition to the results detailed in Example 1 for the aS 
integrin KO mice (FIGS. 1 to 5), IgG immunohistochemistry 45 
was performed to determine potential differences in post-
strokeBBBpermeability onPSDl and3 (FIG. 6). IgGimmu-
noreactivity was abundant in all of the brains of stroked WT 
mice at both PSDs, but was not detected in any of the aS 
integrin KO mice brains (n=6). This supports the notion that 50 
that the absence of endothelial cell aS integrin promotes 
post-stroke BBB integrity. 
Example 3 
OGD exposed cells+/-ATN-161 treatment (data not shown), 
ATN -161 blocked the OGD-mediated increase in endothelial 
cell permeability to FITC-dextran (FIG. 9). As the 8 hour 
OGD-24 hour reperfusion protocol did not cause significant 
endothelial cell death or detachment (trypan blue cell exclu-
sion assay, data not shown), the ATN-161 effect on perme-
ability caunot be simply attributed to potential OGD cell 
protection. This Example supports the notion that inhibition 
of brain endothelial cell aS~ 1 integrin stabilizes brain endot-
helial cell permeability under stroke-like (OGD-reperfusion) 
conditions. 
This Example describes procedures performed to charac-
terize the potential of the aS~ 1 integrin as a therapeutic target 
for ischemic stroke. As discussed above, aS integrin KO mice 
suggest that the aS~ 1 integrin could represent an effective 
stroke therapeutic target. In this Example, this therapeutic 
quality will be investigated by determining whether inhibi-
tion of the more specific aS~l integrin in WT mice after 
MCAo results in resistance to ischemic injury and improved 
functional outcomes mirroring the results seen in stroked aS 
integrin KO mice. 
55 Next, it was determined that ATN-161 could block the 
OGD-induced increase in aS~l integrin expression in WT 
brain endothelial cells (FIGS. lOA and lOB), supporting the 
notion that inhibiting aS~ 1 integrin might help stabilize brain 
endothelial cell permeability, in part, by preventing an 
increase in aS~l integrin expression. 
To determine the therapeutic potential of blocking the 
aS~ 1 integrin after MCAo, 3 month old male WT mice were 
treated withATN-161 or PBS vehicle control12 hours after 
60 The studies also demonstrated that ATN -161 could prevent 
the OGD-mediated decrease in claudin-S expression, as mea-
sured by western blot and immunocytochemistry, in mouse 
brain endothelial cells, which could be inhibited by the PKA 
specific inhibitor PKI (FIGS. llA to llC). It was noted that 
65 Ac-PhScN-NH2 was more effective than ATN-161 in fur-
ther increasing claudin-S levels above normoxic control lev-
els. 
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Next, to demonstrate whether absent brain endothelial cell 
aS~ 1 integrin could affect claudin-S expression after stroke, 
claudin-S qPCR was performed on PSD1 from the stroked 
and sham cerebral hemispheres of aS integrin KO mice and 
WT littermates. While sham claudin-S levels were identical 5 
between the two genotypes, claudin-S gene expression 
increased by 60% in stroked aS integrin KO mice relative to 
stroked WT littermate controls, suggesting that endothelial 
cell knockdown of aS~ 1 integrin positively effects claudin-S 
gene expression after ischemic stroke. 10 
While the terms used herein are believed to be well under-
stood by one of ordinary skill in the art, definitions are set 
forth herein to facilitate explanation of the presently-dis-
closed subject matter. 
Unless defined otherwise, all technical and scientific terms 15 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently-
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently- 20 
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer- 25 
ence to "an inhibitor" includes a plurality of such inhibitors, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 30 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 35 
subject matter. 
As used herein, the term "about," when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments ±20%, in some embodiments ±10%, in some 40 
embodiments ±S%, in some embodiments ±1 %, in some 
embodiments ±O.S%, and in some embodiments ±0.1% from 
the specified amount, as such variations are appropriate to 
perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 45 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" is 50 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, ifl 0 and 
1S are disclosed, then 11, 12, 13, and 14 are also disclosed. 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by refer- 55 
ence. 
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<160> NUMBER OF SEQ ID NOS, 1 
<210> SEQ ID NO 1 
<211> LENGTH, 9 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized 
<400> SEQUENCE, 1 
Cys Arg Arg Glu Thr Ala Trp Ala Cys 
1 5 
What is claimed is: 
1. A method for treating ischemia in a subject, comprising: 
administering to a subject in need thereof an effective amount 
of a a5 ~ 1 integrin inhibitor thereby treating the ischemia, 
wherein the ischemia is caused by an ischemic event 
selected from cerebral ischemia and/or stroke, 
16 
8. A method for preventing an infarction caused by a cere-
bral ischemia event in a subject, comprising: administering to 
a subject in need thereof an effective amount of a a5~1 
20 integrin inhibitor thereby preventing the infarction, 
wherein prior to the step of administering the a5~ 1 integrin 
inhibitor, the subject is diagnosed as having cerebral 
ischemia, and wherein the a5~1 integrin inhibitor is ATN-161 or 
Ac-PhScN-NH2 . 25 
2. Themethodofclaim1, whereinthea5~1 integrininhibi-
and wherein the a5~1 integrin inhibitor is ATN-161 or 
Ac-PhScN-NH2 . 
9. The method of claim 8, wherein the a5 ~ 1 integrin inhibi-
tor is administered during, or after the cerebral ischemic 
event. 
tor is administered during or after the onset of the ischemia. 
3. Themethodofclaim1, whereinthea5~1 integrininhibi-
tor is administered about 0.5 hours to about 30 hours after the 
onset of the ischemia. 
4. Themethodofclaim1, whereinthea5~1 integrininhibi-
tor is administered prior to the onset of ischemia. 
5. The method of claim 1, wherein the treatment prevents 
the occurrence of an infarction. 
10. The method of claim 9, wherein the a5~1 integrin 
30 inhibitor is administered about 0.5 to about 30 hours after the 
cerebral ischemic event. 
11. The method of claim 8, wherein about 5% to about 95% 
of infarction is prevented in the subject relative to a control 
subject. 6. The method of claim 1, wherein the treatment restores 
perfusion to organs and tissues. 
35 12. The method of claim 8, wherein the administering step 
includes administering about 1 mg/kg to about 50 mg/kg of 
the a59~1 integrin inhibitor. 7. The method of claim 1, wherein the administering step includes administering about 1 mg/kg to about 50 mg/kg of 
the a5~1 integrin inhibitor. 
* * * * * 
